Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 7
MISBP 2024

Application of Neuroinformatics in Alzheimer's Disease Research

Juncheng Xie *

College of SDU-ANU Joint Science, Shandong University, Weihai, China

* Corresponding Author: 202200700286@mail.sdu.edu.cn

Abstract. Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the gradual decline in cognitive function, and its complex pathological mechanisms remain incompletely understood. As an interdisciplinary field that integrates multimodal data, neuroinformatics has played a crucial role in Alzheimer's disease research in recent years. This review systematically explores the application of neuroinformatics in Alzheimer's disease research, covering key databases and resources (e.g., ADNI and GAAIN), imaging technologies (e.g., MRI, fMRI, EEG, PET), and data analysis algorithms (e.g., support vector machines, convolutional neural networks). Neuroinformatics techniques have provided new pathways for early diagnosis, risk prediction, and personalized treatment of Alzheimer's disease by integrating imaging, genomic, behavioral, and clinical data to reveal changes in brain function and structure in AD patients. In the future, with the strengthening of big data platforms and international collaborations, neuroinformatics will further promote the development of precision medicine in Alzheimer's disease and provide stronger support for new treatment strategies.

Keywords: Neuroinformatics; Alzheimer's disease; Data analysis; Imaging technology.

1. Introduction

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive and irreversible decline in cognitive abilities and memory loss [1]. Its pathological features include the accumulation of Aβ in the brain parenchyma and vascular system, neurofibrillary tangles (NFTs) caused by hyperphosphorylated tau protein (pTau), and activation of microglia and astrocytes, leading to chronic neuroinflammation, synaptic dysfunction, neuronal loss, and brain atrophy [2]. Due to the complexity of AD, significant progress has not yet been made in treating the disease.

In the mild stage of Alzheimer's dementia, patients can usually perform most daily activities independently but may need assistance with complex tasks. In the moderate stage, memory and language functions further deteriorate, making daily tasks difficult, with symptoms such as cognitive confusion and behavioral changes. In the severe stage, communication ability is greatly reduced, and patients lose self-care abilities, often requiring round-the-clock care [3]. The increasing demands on global healthcare systems and societal resources, particularly in long-term care facilities and support services, place a heavy burden on society.

Neuroinformatics is an interdisciplinary field that integrates computational methods and informatics techniques to analyze and model multimodal data to understand brain structure and function [4]. Neuroinformatics methods combine brain imaging technologies (such as functional magnetic resonance imaging, fMRI, positron emission tomography, PET), electrophysiological recordings, genetic information, and behavioral data, enabling researchers to explore the relationships between different data types and delve deeper into the neural mechanisms and pathological states, thus promoting the development of precision medicine.

Neuroinformatics has played a key role in Alzheimer's disease research by analyzing complex neural data, deepening the understanding of AD, and providing important support for formulating effective treatment strategies [5]. In AD research, neuroinformatics techniques such as fMRI, EEG, and PET have revealed structural and functional changes in the brains of AD patients [6]. fMRI has been widely used to study abnormal brain network function in AD and its precursor disease—mild cognitive impairment (MCI); EEG has been employed to explore the impact of AD on brain activation

systems and cortical circuits. PET, using molecular imaging techniques, allows for the visualization and tracking of pathological changes in AD and MCI in vivo. Additionally, neuroinformatics relies on machine learning and data mining techniques to extract features from multimodal data and conduct predictive analysis, which is crucial for early diagnosis and personalized treatment of AD.

In recent years, several large research projects have generated open multi-omics datasets to advance AD research and drug development. For instance, the Accelerating Medicines Partnership-Alzheimer's Disease project (AMP-AD) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) are changing traditional paradigms of AD diagnosis and therapeutic development [7]. These projects, utilizing neuroinformatics methods, have enhanced the understanding of AD and accelerated the development of novel diagnostic tools and therapeutic approaches.

This review aims to systematically explore the application of neuroinformatics in Alzheimer's disease research, covering aspects from data resources and imaging technologies to data analysis and algorithms. By analyzing the existing literature and research findings, we hope to provide new perspectives for future AD research and identify potential challenges and opportunities in this field.

2. Databases and Resources in Neuroinformatics

The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004, led by Dr. Michael W. Weiner. ADNI is a five-year public-private partnership research project aimed at tracking the progression of Alzheimer's disease (AD) and mild cognitive impairment (MCI) through MRI and PET scans and clinical measures. ADNI has undergone five phases (ADNI1, ADNI GO, ADNI2, ADNI3, ADNI4), and its research has revealed a wealth of knowledge about brain aging and AD, advancing the understanding and treatment of the disease. Research has found that ADNI data reveal evidence supporting the central role of beta-amyloid (Aβ) in disease progression and differences between it and other potential factors [8]. For instance, targeting only Aβ42 in cerebrospinal fluid (CSF) may overlook the contribution of other Aβ isoforms. In studies involving the ADNI and BioFINDER cohorts, higher levels of CSF Aβ38 were associated with the conversion of MCI to AD dementia [9]. This suggests that different Aβ isoforms may also play important roles in disease progression.

The Global Alzheimer's Association Interactive Network (GAAIN) aims to build a shared platform that aggregates research data, analytical tools, and computational resources from multiple institutions for studying the etiology of Alzheimer's disease. The core design of this network emphasizes respect for data ownership and prevents unauthorized data distribution while maintaining the boundaries of contributing institutions. GAAIN provides visualized data query results, displaying graphical and summary tables to ensure data security while enabling researchers to discover new datasets. By integrating multimodal data such as neuroimaging, genetics, and demographics, GAAIN offers a virtual community for Alzheimer's disease research [10].

UK Biobank is a large biomedical database containing health data from 500,000 volunteers, covering electronic health records (EHR), genomic data, and imaging data. UK Biobank's unique contribution to Alzheimer's disease research lies in its provision of large-scale genomic and biomarker data, supporting global health research and medical innovation.

The Laboratory of Neuro Imaging (LONI) database provides rich structural and functional MRI, PET scan data for neuroimaging research. In Alzheimer's disease research, LONI data have contributed to tracking disease progression, identifying early brain structure and function changes, and supporting cross-population comparative studies.

3. The Application of Magnetic Resonance Imaging (MRI) in Alzheimer's Disease

Neuroimaging technologies such as functional magnetic resonance imaging (fMRI), structural magnetic resonance imaging (sMRI), electroencephalography (EEG), and positron emission tomography (PET) generate large amounts of complex data. With the rise of multi-site collaborative

research, the difficulty of using these large datasets increases, highlighting the need for more powerful tools to manage and analyze this data. Neuroinformatics facilitates standardized data storage and retrieval processes, enabling researchers to easily access and share data, simplifying studies involving large cohorts [11]. The combination of these services with data repositories also reduces research challenges caused by data fragmentation.

In multimodal data integration, data standardization is critical. It not only avoids analysis biases caused by different data formats or ranges but also ensures data comparability across studies. Data interoperability promotes data sharing and collaboration across institutions, enhancing research efficiency and allowing researchers to integrate information across different data platforms, expanding the potential applications of data.

Structural magnetic resonance imaging (sMRI) is an important tool for detecting morphological changes caused by brain atrophy and has been widely used for early detection of Alzheimer's disease [12]. sMRI can non-invasively capture deep structural changes associated with brain atrophy. Various computer-aided diagnostic (CAD) methods have been proposed for early diagnosis of AD [13]. For example, deep learning methods such as convolutional neural networks (CNN) have been used to diagnose AD from sMRI data and have shown superior performance compared to traditional manual feature extraction methods [14]. The hierarchical fully convolutional network (H-FCN) proposed by Lian et al. can automatically identify discriminative locations in sMRI data for Alzheimer's disease diagnostic tasks, including AD classification and MCI conversion prediction [15].

Functional magnetic resonance imaging (fMRI) is an imaging technique based on measuring brain blood flow that provides dynamic assessments of brain activity. Task-based fMRI can help reveal changes in brain activation in AD patients during specific cognitive tasks, such as reduced activity in the hippocampus and prefrontal areas, which are closely related to cognitive dysfunction [16]. Resting-state fMRI provides insights into functional networks associated with Alzheimer's disease, particularly the default mode network (DMN), which shows increased neural activity at rest and is thought to be related to AD pathology. Studies have found that brain regions involved in the DMN, such as the posterior cingulate cortex (PCC) and medial prefrontal cortex, show reduced functional connectivity in AD patients [17].

Diffusion tensor imaging (DTI) is another MRI technique that helps study Alzheimer's disease by quantifying the direction and rate of water molecule diffusion within tissue to infer microstructural changes in white matter. In age-related studies, DTI has been shown to be more sensitive than volumetric measurements in capturing white matter degeneration, providing more clues for the early detection of Alzheimer's disease [18].

4. The Application of Electroencephalography (EEG) in Alzheimer's Disease

Electroencephalography (EEG) is a technique used to monitor changes in brain electrical activity. In Alzheimer's disease (AD) research, EEG can reveal abnormal electrical wave patterns caused by neurodegenerative lesions, helping with early detection and assessing disease progression. Due to its high temporal resolution, EEG is valuable for monitoring AD progression and evaluating treatment effects. Bickford et al. introduced compressed spectral arrays or spectrograms to display EEG activity over time in three-dimensional images for anesthetized patients [19]. Levy utilized multiple EEG features to track the effects of anesthesia and further explored the relationship between anesthetic dosage, EEG patterns, and patient arousal levels [20, 21].

EEG can study the synchronous activity between groups of neurons, which is critical for understanding the coordinated function of neural networks. Its high temporal resolution allows researchers to analyze the temporal characteristics of neural signals, identifying signal transmission delays and speeds. By analyzing the electrical activity of different brain regions, EEG can reveal how neural signals are transmitted between regions, helping to determine the role of specific brain areas in cognitive and perceptual tasks. Additionally, EEG is widely used to study abnormalities in neural

signal transmission in diseases such as epilepsy and Alzheimer's, providing important clues for diagnosis and treatment.

Studies have shown that in AD patients, functional connectivity in the alpha and beta bands (AEC-c) significantly decreases, while connectivity in the theta band increases. Changes in these bands are early features of AD, especially the reduced beta-band AEC-c in the bilateral temporal and parietal cortices, which is most pronounced [22]. This change in functional connectivity is not only a specific marker of AD but is also closely related to the severity of the disease [23]. Among patient subgroups meeting the amyloid, tau, and neurodegeneration (A/T/N) criteria, these band effects are more pronounced, further proving the disease specificity of these changes. It was also found that the decrease in alpha-band AEC-c values was moderately correlated with a decline in MMSE (Mini-Mental State Examination) scores, indicating that EEG can be used to assess disease severity.

EEG can also be combined with other neuroimaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET). fMRI provides high spatial resolution information on changes in brain blood flow, revealing patterns of activity and functional connectivity in different brain regions. PET, on the other hand, can detect brain metabolic activity and pathological features, such as the distribution of amyloid plaques and tau protein, which are important for detecting early pathological features of Alzheimer's disease.

5. Data Analysis and Algorithms in Neuroinformatics

In neuroinformatics, machine learning and deep learning technologies play key roles in processing and analyzing complex brain imaging data. Support vector machines (SVMs) are a classification algorithm widely used in high-dimensional data analysis that effectively classifies data by finding the optimal hyperplane. SVMs are particularly suited for processing brain imaging data and helping analyze different neural network functions [24].

Random forests are an algorithm that aggregates multiple decision trees, using a voting mechanism to improve classification accuracy, especially for handling complex and nonlinear neural datasets. This method can effectively perform feature selection, identifying key brain regions or genetic traits associated with Alzheimer's disease [25]. Convolutional neural networks (CNNs) perform exceptionally well in image processing and have been widely applied in Alzheimer's disease brain imaging classification and segmentation. By extracting image features through convolutional layers, CNNs can automatically identify structural changes associated with the disease.

Recurrent neural networks (RNNs), on the other hand, are more suitable for processing sequential data, such as EEG signals, and can capture temporal dependencies, analyzing dynamic changes in brain electrical activity. RNNs allow researchers to extract important patterns related to neural function or disease progression from time-series data [26].

Using neuroinformatics data (e.g., brain imaging, genomic data), machine learning models can be trained and predict the risk and progression of Alzheimer's disease through multimodal data fusion. These models combine brain structure, function, and genetic data, significantly improving early detection and prediction of the disease. However, model accuracy depends on the quality and diversity of the data. Data heterogeneity, individual differences, and model interpretability remain challenges that need to be addressed.

In neural network research, network analysis methods (e.g., graph theory) have been widely used to identify functional connectivity changes between brain regions in Alzheimer's disease patients. By analyzing functional connectivity maps, researchers can reveal the impact of the disease on the topological structure of brain networks, discovering potential biomarkers. These biomarkers help in understanding disease mechanisms, promoting early diagnosis, and providing a basis for personalized treatment [27].

6. Future Prospects of Neuroinformatics in Alzheimer's Disease Research

Neuroinformatics techniques such as functional magnetic resonance imaging (fMRI) and structural magnetic resonance imaging (sMRI) have played an important role in Alzheimer's disease (AD) research. By providing detailed images of brain structure and function, researchers can identify specific brain region changes associated with Alzheimer's disease. fMRI measures brain activity during task performance or resting states, revealing abnormal changes in brain functional networks, while diffusion tensor imaging (DTI) is used to assess white matter integrity, providing rich data for studying neurodegenerative changes in Alzheimer's disease [28]. Electroencephalography (EEG) is also used to monitor changes in brain electrical activity, especially the weakening of functional connectivity in the alpha and beta bands, which are early pathological features of Alzheimer's disease.

In genomics, the application of high-throughput sequencing technologies has made it possible to deeply analyze large-scale genomic and transcriptomic data. For example, genome-wide association studies (GWAS) have identified multiple genes associated with Alzheimer's disease risk, such as APOE and TREM2. RNA sequencing technology has revealed transcriptomic changes, helping researchers discover new potential biomarkers, which contribute to understanding the molecular mechanisms and progression of Alzheimer's disease [29].

Data-sharing platforms have played a key role in promoting Alzheimer's disease research. Large databases such as ADNI and UK Biobank provide vast amounts of clinical, imaging, and genetic data, offering robust support for global research collaborations. Through the integration and analysis of big data, different research teams can make faster progress, promoting international collaborative projects such as GAAIN (Global Alzheimer's Association Interactive Network), which integrates multisource data from around the world, providing new perspectives for understanding the pathological mechanisms of Alzheimer's disease [30].

Future research will rely on more international collaborations and more advanced technological developments. The continuous advancement of neuroinformatics technologies enables the integration and analysis of multimodal data, which not only helps deepen the understanding of disease mechanisms but also promotes the development of personalized treatments. By combining imaging, genomic, and clinical data, researchers are expected to develop more precise diagnostic tools and personalized treatment plans.

7. Conclusion

Neuroinformatics in Alzheimer's disease research is facing challenges such as data complexity and the demand for computational resources. With the rapid growth of big data, effectively storing, processing, and analyzing this data has become a major challenge. Additionally, many existing algorithms require high computational resources, placing pressure on some research institutions. Therefore, developing more efficient data processing tools and computational methods will be an important direction in future research.

Refined classification of disease subtypes will help better understand the manifestations of the disease in different patients. By combining imaging data, genomic data, and clinical characteristics, researchers can identify more specific disease subtypes and tailor personalized treatment plans for different subtypes. Personalized treatment not only needs to be based on the individual's genetic background but also needs to integrate their brain imaging data and lifestyle factors, driving the development of more precise medicine.

Neuroinformatics technologies have shown great potential in the early detection and risk prediction of Alzheimer's disease. By integrating multimodal data, including brain imaging, genomics, and biomarkers, machine learning models can be trained to predict disease progression. These models not only improve the ability for early detection but also provide personalized risk assessments and intervention strategies based on the individual's specific genetic background and clinical data.

Large comprehensive databases such as ADNI and UK Biobank provide rich data resources for Alzheimer's disease research. These databases aggregate extensive multimodal data, facilitating cross-institutional, interdisciplinary collaboration. High-performance computing technologies and data mining algorithms, such as random forests and support vector machines (SVM), play key roles in analyzing complex neuroscience data. These technologies can extract useful information from large datasets and help discover key biomarkers related to Alzheimer's disease.

Future research is expected to further reveal the complex pathological mechanisms of Alzheimer's disease. By integrating and analyzing data, researchers will be able to gain deeper insights into early biomarkers and key pathological processes of the disease. This will help develop new prevention and treatment strategies and provide a more precise foundation for personalized medical plans. The use of artificial intelligence and big data analysis technologies will not only improve the accuracy of Alzheimer's disease diagnosis but also optimize treatment plans, ensuring the personalization and effectiveness of treatment. Additionally, more interdisciplinary collaboration will drive innovative convergence between medicine and other fields, bringing new opportunities to solve complex health problems.

References

[1] McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., ... (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7 (3), 263 – 269.

[2] Scheltens, P., Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2021). Alzheimer's disease. Lancet, 397 (10293), 1577 – 1590.

[3] Alzheimer's Association. (2024). Alzheimer's disease facts and figures. Alzheimer's & Dementia, 20 (5), 3708 – 3821.

[4] Koch, C., & Segev, I. (2000). Methods in neuronal modeling: From ion channels to networks. MIT Press.

[5] Glover, G. H. (2011). Overview of functional magnetic resonance imaging. Neurosurgical Focus, 27 (5), E4.

[6] Suppiah, S., Didier, M. A., & Vinjamuri, S. (2019). The who, when, why, and how of PET amyloid imaging in management of Alzheimer's disease: Review of literature and interesting images. Diagnostics (Basel), 9 (2), 65.

[7] Hodes, R. J., & Buckholtz, N. (2016). Accelerating Medicines Partnership: Alzheimer's disease (AMP-AD) knowledge portal aids Alzheimer's drug discovery through open data sharing. Expert Opinion on Therapeutic Targets, 20 (4), 389 – 391.

[8] Van Dyck, C. H., Swanson, C. J., Aisen, P., et al. (2022). Lecanemab in early Alzheimer's disease. The New England Journal of Medicine, 388, 9 – 21.

[9] Cullen, N., Janelidze, S., Palmqvist, S., et al. (2022). Association of CSF Abeta38 levels with risk of Alzheimer disease-related decline. Neurology, 98, e958 – e967.

[10] Neu, S. C., Crawford, K. L., & Toga, A. W. (2016). Sharing data in the global Alzheimer's Association interactive network. NeuroImage, 124 (Pt B), 1168 – 1174.

[11] Amari, S.-I., Beltrame, F., Bjaalie, J. G., Dalkara, T., De Schutter, E., Egan, G. F., Goddard, N. H., Gonzalez, C., Grillner, S., Herz, A., Hoffmann, K. P., Jaaskelainen, I., Koslow, S. H., Lee, S. Y., Matthiessen, L., Miller, P. L., Da Silva, F. M., Novak, M., Ravindranath, V., Ritz, R., Ruotsalainen, U., Sebestra, V., Subramaniam, S., Tang, Y., Toga, A. W., Usui, S., Van Pelt, J., Verschure, P., Willshaw, D., & Wrobel, A. (2002). Neuroinformatics: The integration of shared databases and tools towards integrative neuroscience. Journal of Integrative Neuroscience, 1, 117 – 128.

[12] Toga, A. W. (2002). Neuroimage databases: The good, the bad and the ugly. Nature Reviews Neuroscience, 3, 302 – 309.

[13] Rathore, S., Habes, M., Iftikhar, M. A., Shacklett, A., & Davatzikos, C. (2017). A review on neuroimaging-based classification studies and associated feature extraction methods for Alzheimer's disease and its prodromal stages. NeuroImage, 155, 530 – 548.

[14] Shin, H.-C., Roth, H. R., Gao, M., Lu, L., Xu, Z., Nogues, I., ... (2016). Deep convolutional neural networks for computer-aided detection: CNN architectures, dataset characteristics and transfer learning. IEEE Transactions on Medical Imaging, 35 (5), 1285 – 1298.

[15] Whitwell, J. L., Dickson, D. W., Murray, M. E., Weigand, S. D., Tosakulwong, N., Senjem, M. L., ... (2012). Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: A case-control study. Lancet Neurology, 11 (10), 868 – 877.

[16] Casanova, R., Whitlow, C. T., Wagner, B., Williamson, J., Shumaker, S. A., Maldjian, J. A., & Espeland, M. A. (2011). High dimensional classification of structural MRI Alzheimer's disease data based on large scale regularization. Frontiers in Neuroinformatics, 5, 22.

[17] Greicius, M. D., Krasnow, B., Reiss, A. L., & Menon, V. (2003). Functional connectivity in the resting brain: A network analysis of the default mode hypothesis. Proceedings of the National Academy of Sciences, 100, 253 – 258.

[18] Cerebral white matter integrity and cognitive aging: Contributions from diffusion tensor imaging. (2009). Neuropsychology Review, 19, 415 – 435.

[19] Bickford, R. G., Fleming, N., & Billinger, T. (1971). Compression of EEG data. Transactions of the American Neurological Association, 96, 118 – 122.

[20] Levy, W. J. (1984). Intraoperative EEG patterns: Implications for EEG monitoring. Anesthesiology, 60, 430 – 434.

[21] Tinker, J. H., Sharbrough, F. W., & Michenfelder, J. D. (1977). Anterior shift of the dominant EEG rhythm during anesthesia in the Java monkey: Correlation with anesthetic potency. Anesthesiology, 46, 252 – 259.

[22] Koelewijn, L., Bompas, A., Tales, A., Brookes, M. J., Muthu Kumaraswamy, S. D., Bayer, A., ... (2017). Alzheimer's disease disrupts alpha and beta-band resting-state oscillatory network connectivity. Clinical Neurophysiology, 128 (11), 2347 – 2357.

[23] Colclough, G. L., Woolrich, M. W., Tewarie, P. K., Brookes, M. J., Quinn, A. J., & Smith, S. M. (2016). How reliable are MEG resting-state connectivity metrics? NeuroImage, 138, 284 – 293.

[24] Gass, A., Dey, S., & Mateen, M. (2015). Machine learning algorithms for disease classification using multi-omics data. PLOS ONE, 10 (7), e0133803.

[25] Yao, J., & Xu, Y. (2019). A comprehensive review of deep learning in medical imaging. International Journal of Medical Informatics, 130, 103964.

[26] Zhang, D., & Shen, D. (2012). Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLOS ONE, 7 (3), e33182.

[27] Bullmore, E., & Sporns, O. (2009). Complex brain networks: Graph theoretical analysis of structural and functional systems. Nature Reviews Neuroscience, 10 (3), 186 – 198.

[28] Jack, C. R., Bennett, D. A., Blennow, K., ... (2018). NIA-AA research framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia, 14 (4), 535 – 562.

[29] Karch, C. M., Cruchaga, C., & Goate, A. M. (2014). Alzheimer's disease genetics: From the bench to the clinic. Neurobiology of Disease, 72, 1 – 11.

[30] Sperling, R. A., Aisen, P. S., Beckett, L. A., ... (2014). Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia, 7 (3), 280 – 292.